Colgate Palmolive
Colgate-Palmolive (India) Ltd
- P/E
- 33.17
Key Fundamentals
MidcapPersonal ProductsFMCGPrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 108.00%
- Debt to Equity
- 0.03
- EPS (TTM)
- ₹50.07
- Book Value
- ₹59.48
- Market Cap
- —
- P/E (TTM)
- 33.17
- P/B
- 27.92
- ROE
- 82.70%
- Dividend Yield
- 1.47%
- EBITDA
- ₹1,959 Cr
- 52W High
- ₹2,301.60
- 52W Low
- ₹1,563.90
- Day Range
- ₹1,623.30 – ₹1,674.40
- Volume
- 6,33,685
Peer Comparison
Fast Moving Consumer Goods › Consumer Goods › Personal Care
| ₹849.00 | 45.38 | ₹86,648 Cr | 6.89 | 1.82% | 16.10% | 18.80% | ₹15,949 Cr | ₹1,914 Cr | |
| ₹395.00 | 35.52 | ₹69,681 Cr | 6.14 | 2.16% | 17.00% | 20.30% | ₹13,552 Cr | ₹1,947 Cr | |
| Colgate Palmolive (this company) | ₹1,660.70 | 33.17 | ₹45,422 Cr | 27.92 | 1.47% | 82.70% | 108.00% | ₹6,391 Cr | ₹1,362 Cr |
| ₹336.50 | 329.90 | ₹44,683 Cr | 100.45 | 1.48% | 27.60% | 33.90% | ₹484 Cr | ₹137 Cr | |
| ₹7,527.00 | 36.71 | ₹23,745 Cr | 25.92 | 3.32% | 66.50% | 90.70% | ₹3,176 Cr | ₹668 Cr | |
| ₹6,959.00 | 28.57 | ₹22,555 Cr | 29.98 | 3.61% | 115.00% | 157.00% | ₹4,245 Cr | ₹790 Cr | |
| ₹381.35 | 22.24 | ₹16,773 Cr | 5.69 | 2.62% | 26.20% | 28.10% | ₹3,915 Cr | ₹749 Cr | |
| Median 7 companies | ₹849.00 | 35.52 | ₹44,683 Cr | 25.92 | 2.16% | 27.60% | 33.90% | ₹4,245 Cr | ₹790 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 85
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 38
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 50
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 91
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 23
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 46
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 79.4%
- Company has been maintaining a healthy dividend payout of 112%
Weaknesses
2- Stock is trading at 27.0 times its book value
- The company has delivered a poor sales growth of 4.51% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 5 | 3 |
| Oscillators | Bearish | 3 | 5 | 1 |
| Moving Averages | Strong Bearish | 8 | 0 | 2 |
Oscillators
Bearish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 44.06
- Neutral
- MACD (12,26,9)
- −55.25
- Bearish
- SMA (50)
- 1,781.16
- Bearish
- SMA (200)
- 1,994.96
- Bearish
As of
Analyst Rating
7 of 26 analysts rate Buy, 9 Hold, 10 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +4.55% |
|---|---|
| 5Y | +4.51% |
| 3Y | +4.91% |
| 1Y | −0.08% |
| TTM | +8.69% |
Net profit
| 10Y | +8.59% |
|---|---|
| 5Y | +5.06% |
| 3Y | +8.17% |
| 1Y | −7.79% |
| TTM | +2.64% |
Operating cash flow
| 10Y | +10.12% |
|---|---|
| 5Y | +18.16% |
| 3Y | +15.37% |
| 1Y | +29.56% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +6.69 pp |
|---|---|
| 5Y | −0.20 pp |
| 3Y | +1.39 pp |
| 1Y | −1.43 pp |
| TTM | −1.95 pp |
Revenue by year
| Mar 2017 | ₹3,982 Cr |
|---|---|
| Mar 2018 | ₹4,188 Cr |
| Mar 2019 | ₹4,462 Cr |
| Mar 2020 | ₹4,525 Cr |
| Mar 2021 | ₹4,841 Cr |
| Mar 2022 | ₹5,100 Cr |
| Mar 2023 | ₹5,226 Cr |
| Mar 2024 | ₹5,680 Cr |
| Mar 2025 | ₹6,040 Cr |
| Mar 2026 | ₹6,035 Cr |
Net profit by year
| Mar 2017 | ₹577 Cr |
|---|---|
| Mar 2018 | ₹673 Cr |
| Mar 2019 | ₹776 Cr |
| Mar 2020 | ₹816 Cr |
| Mar 2021 | ₹1,035 Cr |
| Mar 2022 | ₹1,078 Cr |
| Mar 2023 | ₹1,047 Cr |
| Mar 2024 | ₹1,324 Cr |
| Mar 2025 | ₹1,437 Cr |
| Mar 2026 | ₹1,325 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
As of 2026-11-03, Colgate-Palmolive (India) trades at ₹1,631.7 with a market cap of ₹43,469 Cr, a P/E of 32.59x and an exceptionally high ROE of 83.66%. The stock sits 29% below its 52-week high of ₹2,301.6 and has delivered a negative 1-year stock CAGR of -28%, while the underlying business remains virtually debt-free with steady single-digit revenue and profit growth.
- Near-zero leverage with a debt-to-equity ratio of just 0.03, providing significant financial resilience and flexibility for future investment or shareholder returns.
- Exceptional return on equity of 83.66% (last year) backed by a consistent 3-year average ROE of 79% and a 10-year average of 66%, indicating highly efficient capital deployment.
- Outstanding return on capital employed of 107.36%, reflecting the company's ability to generate outsized returns on every rupee of capital invested in the business.
- Healthy dividend payout ratio of 112% with a current dividend yield of 1.52%, rewarding shareholders with consistent cash returns well above what many FMCG peers offer at similar valuations.
- TTM revenue growth has accelerated to 9% compared to the 5-year compounded sales growth of 5%, suggesting a recent pickup in top-line momentum.
- Steady 10-year compounded sales growth of 5% and profit growth of 8% demonstrate a durable, if modest, long-term earnings trajectory in a defensive consumer staples category.
- Trading at ₹1,631.7 — roughly 29% below its 52-week high of ₹2,301.6 — the recent correction has compressed the stock's valuation relative to its own recent trading history.
- As a dominant player in the Indian oral care category, the company benefits from strong brand recall and distribution reach across urban and rural India, underpinning its consistently high ROE and ROCE metrics.
- The stock trades at 27.43x book value, an extremely elevated P/B multiple that leaves little margin for error and prices in significant future growth.
- One-year stock CAGR of -28% signals significant investor de-rating, with the stock declining sharply from its 52-week high of ₹2,301.6 to ₹1,631.7.
- Five-year compounded sales growth of just 5% and profit growth of only 5% point to sluggish top-line and bottom-line expansion for a company commanding premium valuation multiples.
- TTM profit growth has decelerated to 4% even as sales grew 9%, implying margin compression or rising input costs that are squeezing profitability.
- A P/E of 32.59x on a TTM EPS of ₹50.07 demands sustained earnings acceleration that the company's historical single-digit growth trajectory has not consistently delivered.
- The 3-year stock CAGR of -8% and 5-year CAGR of just 1% indicate prolonged wealth destruction or stagnation for medium-term shareholders despite robust underlying return ratios.
- A dividend payout exceeding 112% of earnings means the company is distributing more than it earns, which is unsustainable long-term and limits retained capital for reinvestment or inorganic growth.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Colgate-Palmolive India's Q2FY27 results were underwhelming, with profit missing estimates and margins contracting sharply due to aggressive ad spending. Revenue growth on a two-year CAGR basis remains modest at around 3%. There are no near-term positive catalysts visible, and broker sentiment is cautious with target cuts. The trend is deteriorating on margins, and investors should watch whether the elevated ad spend translates into volume acceleration in coming quarters.
- EBITDA margin contracts 264 bps Oct 23
EBITDA margin fell to 27.99% in Q2FY27, down 264 bps YoY, driven by a 40% surge in advertising expenditure.
- Modest underlying revenue growth Oct 23
Two-year revenue CAGR stands at just 2.6-3%, signalling limited top-line momentum for the core business.
- Q2 profit misses estimates Oct 23
Net profit of ₹341.57 crore, up only 4.3% YoY, came in below analyst expectations for the quarter.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,471 | 1,396 | 1,490 | 1,497 | 1,619 | 1,462 | 1,463 | 1,434 | 1,520 | 1,486 | 1,595 | 1,603 | 1,706 |
| Expenses | 989 | 927 | 958 | 988 | 1,122 | 1,007 | 964 | 981 | 1,054 | 1,044 | 1,086 | 1,120 | 1,232 |
| Operating Profit | 482 | 468 | 532 | 508 | 497 | 454 | 498 | 453 | 465 | 442 | 510 | 483 | 473 |
| OPM % | 33% | 34% | 36% | 34% | 31% | 31% | 34% | 32% | 31% | 30% | 32% | 30% | 28% |
| Other Income | 21 | 18 | 23 | 23 | 76 | 20 | 19 | 18 | 15 | 31 | 0 | 19 | 22 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 44 | 41 | 42 | 42 | 42 | 41 | 38 | 38 | 37 | 36 | 35 | 39 | 34 |
| PBT | 458 | 443 | 511 | 489 | 530 | 433 | 478 | 432 | 442 | 436 | 474 | 462 | 460 |
| Tax % | 26% | 26% | 26% | 26% | 26% | 25% | 26% | 26% | 26% | 26% | 25% | 26% | 26% |
| Net Profit | 340 | 330 | 380 | 364 | 395 | 323 | 355 | 321 | 328 | 324 | 353 | 343 | 342 |
| EPS (₹) | 12.5 | 12.14 | 13.96 | 13.38 | 14.52 | 11.87 | 13.05 | 11.79 | 12.04 | 11.91 | 12.99 | 12.61 | 12.56 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,982 | 3,868 | 3,982 | 4,188 | 4,462 | 4,525 | 4,841 | 5,100 | 5,226 | 5,680 | 6,040 | 6,035 | 6,391 |
| Expenses | 3,159 | 2,929 | 3,038 | 3,074 | 3,226 | 3,323 | 3,331 | 3,534 | 3,679 | 3,779 | 4,082 | 4,165 | 4,482 |
| Operating Profit | 823 | 940 | 944 | 1,114 | 1,236 | 1,202 | 1,510 | 1,566 | 1,547 | 1,901 | 1,958 | 1,870 | 1,908 |
| OPM % | 21% | 24% | 24% | 27% | 28% | 27% | 31% | 31% | 30% | 33% | 32% | 31% | 30% |
| Other Income | 32 | 7 | 41 | 26 | 68 | 49 | 30 | 26 | 42 | 57 | 139 | 64 | 72 |
| Interest | 0 | 0 | 0 | 0 | 2 | 10 | 7 | 6 | 5 | 5 | 4 | 4 | 4 |
| Depreciation | 75 | 111 | 133 | 157 | 159 | 198 | 182 | 177 | 175 | 172 | 163 | 146 | 145 |
| PBT | 780 | 835 | 851 | 983 | 1,143 | 1,043 | 1,350 | 1,409 | 1,410 | 1,781 | 1,930 | 1,784 | 1,832 |
| Tax % | 28% | 30% | 32% | 32% | 32% | 22% | 23% | 23% | 26% | 26% | 26% | 26% | — |
| Net Profit | 559 | 581 | 577 | 673 | 776 | 816 | 1,035 | 1,078 | 1,047 | 1,324 | 1,437 | 1,325 | 1,362 |
| EPS (₹) | 20.55 | 21.37 | 21.23 | 24.76 | 28.52 | 30.02 | 38.07 | 39.65 | 38.5 | 48.67 | 52.83 | 48.73 | 50.07 |
| Div. Payout % | 58% | 47% | 47% | 97% | 81% | 93% | 100% | 101% | 101% | 119% | 97% | 119% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
| Reserves | 757 | 1,004 | 1,247 | 1,497 | 1,420 | 1,567 | 1,139 | 1,707 | 1,689 | 1,847 | 1,637 | 1,557 | 1,590 |
| Borrowings | 0 | 0 | 0 | 0 | 83 | 102 | 91 | 83 | 69 | 72 | 61 | 47 | 49 |
| Other Liabilities | 932 | 972 | 1,037 | 1,039 | 1,097 | 908 | 1,637 | 1,084 | 1,098 | 1,250 | 1,293 | 1,777 | 1,971 |
| Total Liabilities | 1,702 | 2,003 | 2,311 | 2,564 | 2,626 | 2,604 | 2,894 | 2,902 | 2,883 | 3,197 | 3,019 | 3,408 | 3,638 |
| Fixed Assets | 782 | 1,008 | 1,108 | 1,146 | 1,191 | 1,123 | 1,065 | 963 | 862 | 794 | 776 | 718 | 673 |
| CWIP | 141 | 78 | 167 | 159 | 199 | 190 | 145 | 122 | 114 | 110 | 38 | 27 | 52 |
| Investments | 37 | 31 | 31 | 31 | 31 | 19 | 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 742 | 885 | 1,005 | 1,228 | 1,206 | 1,272 | 1,666 | 1,817 | 1,907 | 2,292 | 2,204 | 2,663 | 2,913 |
| Total Assets | 1,702 | 2,003 | 2,311 | 2,564 | 2,626 | 2,604 | 2,894 | 2,902 | 2,883 | 3,197 | 3,019 | 3,408 | 3,638 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 638 | 689 | 688 | 694 | 983 | 930 | 784 | 1,626 | 1,176 | 1,199 | 1,394 | 1,806 |
| Investing | −272 | −237 | −342 | −207 | −96 | −19 | 71 | −108 | −8 | 79 | 56 | 374 |
| Financing | −385 | −391 | −341 | −380 | −815 | −891 | −956 | −1,091 | −1,087 | −1,195 | −1,671 | −1,422 |
| Net Cash Flow | −18 | 61 | 5 | 107 | 73 | 20 | −101 | 427 | 82 | 83 | −221 | 758 |
| Free Cash Flow | 339 | 417 | 367 | 485 | 879 | 869 | 727 | 1,576 | 1,107 | 1,123 | 1,323 | 1,730 |
| CFO/EBITDA | 103 | 100 | 105 | 93 | 113 | 104 | 76 | 127 | 101 | 88 | 100 | 121 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6 | 10 | 12 | 18 | 17 | 11 | 9 | 16 | 11 | 11 | 14 | 13 |
| Inventory Days | 63 | 72 | 72 | 56 | 58 | 69 | 79 | 78 | 68 | 63 | 76 | 75 |
| Days Payable | 128 | 136 | 148 | 152 | 144 | 142 | 179 | 169 | 155 | 187 | 185 | 275 |
| Cash Conversion Cycle | −59 | −55 | −63 | −79 | −68 | −63 | −91 | −75 | −76 | −113 | −95 | −188 |
| Working Capital Days | −40 | −43 | −39 | −33 | −36 | −23 | −84 | −25 | −32 | −46 | −37 | −59 |
| ROCE % | 114% | 96% | 74% | 71% | 73% | 65% | 92% | 92% | 79% | 97% | 105% | 108% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Colgate Palmolive insights
70 extracted metrics across FY03–FY27.
Documents
- Concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q4 FY25 concall · May 2025Transcript PPT
- Concall · Feb 2025PPT
- Concall · Dec 2024Transcript PPT
- 29 Jul 2026
- 22 May 2026
- General announcements 23 Oct 2026
Frequently Asked Questions about Colgate Palmolive
What does Colgate-Palmolive (India) Ltd do?
Where is Colgate-Palmolive (India) Ltd (COLPAL) listed?
Which sector does Colgate-Palmolive (India) Ltd belong to?
What is the PE ratio of Colgate-Palmolive (India) Ltd?
What is the 52-week high and low of Colgate-Palmolive (India) Ltd?
Does Colgate-Palmolive (India) Ltd pay dividends?
What is the Return on Equity (ROE) of Colgate-Palmolive (India) Ltd?
Company Information
Colgate-Palmolive India Ltd is engaged in manufacturing/ trading of toothpaste, tooth powder, toothbrush, mouthwash and personal care products.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/COLPAL.md for Colgate-Palmolive (India) Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.